{"id":"Genetically_Inspired_Prognostic_Scoring_System_GIPSS_for_Primary_Myelofibrosis_PMF_.v0.0.1","gdl_version":"2.1","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Aurelia Maria Ozora","email":"aurelia.maria.ozora@cambio.se","organisation":"Cambio CDS","date":"2025-05-15"},"lifecycle_state":"Author draft","details":{"en":{"id":"en","copyright":"Â© Cambio CDS","keywords":["genetically","inspired","prognostic","scoring","system","gipss","primary","myelofibrosis","pmf"],"purpose":"To calculate and assess/interpret the total sum for GIPSS for primary myelofibrosis.\n","use":"For karyotype classification, pick:\n- Favorable if normal karyotype or sole abnormalities of 13q-, +9, 20q- , chromosome 1 translocation/duplication or sex chromosome abnormality including -Y.\n- Very high risk if single/multiple abnormalities of -7, i(17q), inv(3)/3q21, 12p-/12p11.2, 11q-/11q23, +21, or other autosomal trisomies, not including +8/+9.\n- Unfavorable if all other abnormalities, except those listed.","misuse":"Not to be used for assessment of the Dynamic International Prognostic Scoring System (DIPPS) for primary myelofibrosis."}},"other_details":{"references":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23. PMID: 29654267; PMCID: PMC6035151.\n\nKuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25. PMID: 30390311.","en":"The Genetically Inspired Prognostic Scoring System (GIPPS) is a prognostic tool that relies exclusively on genetic markers to assess disease risk. It is designed for primary myelofibrosis (PMF)."},"other_contributors":["Aurelia Maria Ozora"]},"definition":{"data_bindings":{"gt0002":{"id":"gt0002","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.genetically_inspired_prognostic_scoring_system_gipss_for_primary_myelofibrosis_pmf.v0","template_id":"openEHR-EHR-OBSERVATION.genetically_inspired_prognostic_scoring_system_gipss_for_primary_myelofibrosis_pmf.v0","elements":{"gt0003":{"id":"gt0003","path":"/protocol[at0004]/items[at0005]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0010|Favorable|","1|local::at0011|Unfavorable|","2|local::at0012|Very high risk|"]},"gt0004":{"id":"gt0004","path":"/protocol[at0004]/items[at0006]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0013|Yes|","1|local::at0014|No|"]},"gt0005":{"id":"gt0005","path":"/protocol[at0004]/items[at0007]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0015|No|","1|local::at0016|Yes|"]},"gt0006":{"id":"gt0006","path":"/protocol[at0004]/items[at0008]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0017|No|","1|local::at0018|Yes|"]},"gt0007":{"id":"gt0007","path":"/protocol[at0004]/items[at0009]","data_type":"DV_ORDINAL","allowed_values":["0|local::at0019|No|","1|local::at0020|Yes|"]}}},"gt0008":{"id":"gt0008","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.genetically_inspired_prognostic_scoring_system_gipss_for_primary_myelofibrosis_pmf.v0","template_id":"openEHR-EHR-OBSERVATION.genetically_inspired_prognostic_scoring_system_gipss_for_primary_myelofibrosis_pmf.v0","elements":{"gt0009":{"id":"gt0009","path":"/protocol[at0004]/items[at0021]","data_type":"DV_COUNT"},"gt0010":{"id":"gt0010","path":"/protocol[at0004]/items[at0022]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0023|Low|","local::at0024|Intermediate-1|","local::at0032|Intermediate-2|","local::at0033|High|"]},"gt0011":{"id":"gt0011","path":"/protocol[at0004]/items[at0026]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0027|94%|","local::at0028|73%|","local::at0029|40%|","local::at0030|14%|"]},"gt0012":{"id":"gt0012","path":"/protocol[at0004]/items[at0031]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0034|26.4 years|","local::at0035|8.0 years|","local::at0036|4.2 years|","local::at0037|2 years|"]}}}},"templates":{},"rules":{"gt0013":{"id":"gt0013","priority":5,"then":["$gt0009|Total score| = $gt0003|Karyotype classification|.value + $gt0004|Type 1/like CALR mutation|.value + $gt0005|ASXL1 mutation|.value + $gt0006|SRSF2 mutation|.value + $gt0007|U2AF1Q157 mutation|.value"],"when":["$gt0003|Karyotype classification| != null","$gt0004|Type 1/like CALR mutation| != null","$gt0005|ASXL1 mutation| != null","$gt0006|SRSF2 mutation| != null","$gt0007|U2AF1Q157 mutation| != null"]},"gt0014":{"id":"gt0014","priority":4,"then":["$gt0010|Risk| = local::at0023|Low|","$gt0011|5-year overall survival| = local::at0027|94%|","$gt0012|Median overall survival| = local::at0034|26.4 years|"],"when":["$gt0009|Total score| == 0"]},"gt0015":{"id":"gt0015","priority":3,"then":["$gt0010|Risk| = local::at0024|Intermediate-1|","$gt0011|5-year overall survival| = local::at0028|73%|","$gt0012|Median overall survival| = local::at0035|8.0 years|"],"when":["$gt0009|Total score| == 1"]},"gt0016":{"id":"gt0016","priority":2,"then":["$gt0010|Risk| = local::at0032|Intermediate-2|","$gt0011|5-year overall survival| = local::at0029|40%|","$gt0012|Median overall survival| = local::at0036|4.2 years|"],"when":["$gt0009|Total score| == 2"]},"gt0017":{"id":"gt0017","priority":1,"then":["$gt0010|Risk| = local::at0033|High|","$gt0011|5-year overall survival| = local::at0030|14%|","$gt0012|Median overall survival| = local::at0037|2 years|"],"when":["$gt0009|Total score| > 2"]}}},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"id":"gt0001","text":"Genetically Inspired Prognostic Scoring System (GIPSS) for Primary Myelofibrosis (PMF)","description":"The Genetically Inspired Prognostic Scoring System (GIPPS) is a prognostic tool that relies exclusively on genetic markers to assess disease risk. It is designed for primary myelofibrosis (PMF), an aggressive myeloid malignancy with a median survival of approximately six years. Currently, allogeneic hematopoietic stem cell transplantation (alloSCT) remains the only potentially curative treatment for PMF. However, alloSCT carries significant risks of treatment-related morbidity and mortality, making personalized risk-benefit assessment essential before proceeding. GIPPS supports clinical decision-making by identifying patients in whom the potential benefits of alloSCT may outweigh the risks, thereby guiding more individualized and informed treatment strategies."},"gt0002":{"id":"gt0002","text":"openEHR-EHR-OBSERVATION.genetically_inspired_prognostic_scoring_system_gipss_for_primary_myelofibrosis_pmf.v0"},"gt0003":{"id":"gt0003","text":"Karyotype classification"},"gt0004":{"id":"gt0004","text":"Type 1/like CALR mutation"},"gt0005":{"id":"gt0005","text":"ASXL1 mutation"},"gt0006":{"id":"gt0006","text":"SRSF2 mutation"},"gt0007":{"id":"gt0007","text":"U2AF1Q157 mutation"},"gt0008":{"id":"gt0008","text":"openEHR-EHR-OBSERVATION.genetically_inspired_prognostic_scoring_system_gipss_for_primary_myelofibrosis_pmf.v0"},"gt0009":{"id":"gt0009","text":"Total score"},"gt0010":{"id":"gt0010","text":"Risk"},"gt0011":{"id":"gt0011","text":"5-year overall survival"},"gt0012":{"id":"gt0012","text":"Median overall survival"},"gt0013":{"id":"gt0013","text":"Total score","description":""},"gt0014":{"id":"gt0014","text":"Low risk","description":""},"gt0015":{"id":"gt0015","text":"Intermediate-1 risk","description":""},"gt0016":{"id":"gt0016","text":"Intermediate-2 risk","description":""},"gt0017":{"id":"gt0017","text":"High risk","description":""}}}},"term_bindings":{}}}